Rucaparib-hydrochloride-AG014699-hydrochloride-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemERucaparibhydrochlorideCat.No.:HY-10617BCASNo.:773059-19-1Synonyms:AG014699hydrochloride;PF-01367338hydrochloride分?式:C??H??ClFN?O分?量:359.83作?靶點(diǎn):PARP作?通路:CellCycle/DNADamage;Epigenetics儲(chǔ)存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Rucaparib(AG014699)hydrochloride?種?服有效的PARP蛋?(PARP-1,PARP-2andPARP-3)抑制劑，對(duì)PARP-1的Ki為1.4nM。Rucaparibhydrochloride六磷酸?糖脫氫酶(H6PD)抑制劑。Rucaparibhydrochloride具有?于去勢(shì)抵抗性前列腺癌(CRPC)研究的潛?。IC50&TargetPARP-1PARP-2PARP-31.4nM(Ki)體外研究Rucaparib(AG014699)hydrochlorideisapossibleN-demethylationmetaboliteofAG14644[1].Rucaparib(0.1,1,10,100μM;24hours)hydrochlorideiscytotoxicandhastheLC50being5?μMinCapan-1(BRCA2mutant)cellsandonly100?nMinMX-1(BRCA1mutant)cells[2].Theradio-sensitizationbyRucaparibhydrochlorideisduetodownstreaminhibitionofactivationofNF-κB,andisindependentofSSBrepairinhibition.RucaparibhydrochloridecantargetNF-κBactivatedbyDNAdamageandovercometoxicityobservedwithclassicalNF-κBinhibitorswithoutcompromisingothervitalinflammatoryfunctions[5].RucaparibhydrochlorideinhibitsPARP-1activityby97.1%ataconcentrationof1μMinpermeabilisedD283Medcells[6].體內(nèi)研究Rucaparib(AG014699)hydrochlorideandAG14584significantlyincreaseTemozolomidetoxicity.Rucaparib(1mg/kg)hydrochloridesignificantlyincreasesTemozolomide-inducedbodyweightloss.Rucaparib(0.1mg/kg)hydrochlorideresultsina50%increaseinthetemozolomide-inducedtumorgrowthdelay[1].Rucaparib(10?mg/kgfori.p.or50,150mg/kgforp.o.;dailyfor5daysperweekfor6weeks)hydrochloride1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEsignificantlyinhibitsthegrowthofthetumor,andthereisonecompletetumorregressionandtwopersistentpartialregressions[2].Rucaparib(150?mg/kg;p.o.;onceperweekfor6weeksorthreetimesperweekfor6weeks)hydrochloridehasgreatestantitumoreffectwiththreecompleteregressions[2].Rucaparib(1mg/kg;i.p.;dailyfor5d)hydrochlorideenhancestheantitumoractivityoftemozolomideandindicatescompleteandsustainedtumorregressioninNB1691andSHSY5Yxenografts[6].AnimalModel:Femaleathymicnudemice,implantedSW620colorectaltumorcells(1×107cellsperanimal)s.c.[1]Dosage:0.1mg/kgincombinationwithTemozolomide(p.o.,200mg/kg),0.05,0.15,and0.5mg/kgincombinationwithTemozolomide(p.o.,68mg/kg)or10mg/kgAdministration:IP,singledosefor0.1mg/kgand10mg/kg,fivedailydosesfor0-0.5mg/kgResult:SignificantlyincreasedTemozolomidetoxicity,showedoutstandingchemosensitizationpotencyandcausedenhancementofTemozolomide-inducedtumorgrowthdelay.AnimalModel:CD-1nudemicebearingestablishedCapan-1xenografts[2]Dosage:10mg/kgor50,100and150?mg/kgAdministration:IPfor10mg/kg;POfor50,100and150?mg/kg,singledose(Pharmacokinetics)Result:Parentdrugwasdetectableintheplasmaonlyat30?minafter10?mg/kgi.pandupto4?hfor50–150?mg/kgp.o..Wasstilldetectableinmostmicereceivingoralrucaparibat3days.Doesnoteasilycrosstheplasmamembrane.AnimalModel:CD-1nudemicebearingestablishedCapan-1xenografts[2]Dosage:10?mg/kgi.p.dailyfor5daysperweekfor6weeks,50or150?mg/kgp.o.daily×fiveweekly×six,150?mg/kgp.o.onceperweekfor6weeksorthreetimesperweekfor6weeks,or150?mg/kgp.o.dailyforfivedaysevery3weeksAdministration:IPorPOResult:10?mg/kgi.p.significantlyinhibitedthegrowthofthetumor,dailyoraladministrationat150?mg/kghadanequivalenteffectontumorgrowthto10?mg/kgi.p..Theschedulewiththegreatestantitumoreffectwasoraladministrationof150?mg/kgonaonceweeklyschedulewiththreecompleteregressions.AnimalModel:CD-1nudemice,NB1691andSHSY5Yxenografts[6]Dosage:1mg/kgAdministration:IP,dailyfor5dincombinationwithTemozolomide(orallydaily×5atadoseof68mg/kg)2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEResult:EnhancedtheantitumoractivityofTemozolomideandindicatedcompleteandsustainedtumorregression.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?SciTranslMed.2021May26;13(595):eabe8226.?ClinCancerRes.2017Feb15;23(4):1001-1011.?Theranostics.2020Jul25;10(21):9477-9494.?IntJMolSci.2020Feb11;21(4):1185.?Talanta.2018Apr1;180:127-132.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].ThomasHD,etal.Preclinicalselectionofanovelpoly(ADP-ribose)polymeraseinhibitorforclinicaltrial.MolCancerTher,2007,6(3),945-956.[2].JMurray,etal.Tumourcellretentionofrucaparib,sustainedPARPinhibitionandefficacyofweeklyaswellasdailyschedules.BrJCancer.2014Apr15;110(8):1977-84.[3].MattShirley,etal.Rucaparib:AReviewinOvarianCancer.TargetOncol.2019Apr;14(2):237-246.[4].JiannengLi,etal.Hexose-6-phosphatedehydrogenaseblockadereversesprostatecancerdrugresistanceinxenograftmodelsbyglucocorticoidinactivation.SciTranslMed.2021May26;13(595):eabe8226.[5].HunterJE,etal.NF-κBmediatesradio-sensitizationbythePARP-1inhibitor,AG-014699.Oncogene,2012,31(2),251-264.[6].DanielRA,etal.Inhibitionofpoly(ADP-ribose)polymerase-1enhancestemozolomideandtopotecanactivityagainst